2001
DOI: 10.1161/hy09t1.092927
|View full text |Cite
|
Sign up to set email alerts
|

Gene Therapy for Hypertension

Abstract: Abstract-Despite several drugs for the treatment of hypertension, there are many patients with poorly controlled high blood pressure. This is partly because all of the available drugs are short-lasting (Յ24 hours), have side effects, and are not highly specific. Gene therapy offers a possibility of producing longer-lasting effects with precise specificity based on the genetic design. Preclinical studies on gene therapy for hypertension have taken 2 approaches. Chao et al have performed extensive studies on gen… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
9
0

Year Published

2002
2002
2017
2017

Publication Types

Select...
5
2

Relationship

0
7

Authors

Journals

citations
Cited by 38 publications
(9 citation statements)
references
References 45 publications
0
9
0
Order By: Relevance
“…26 Glutamatergic neurotransmission at the NTS is also involved in the downregulation of AT1R mRNA after baroreceptor activation. 21 Angiotensin and glutamate receptors exhibit augmented interaction in the brain of SHR, 32,33 and an elevated basal Fos expression is present in the NTS during hypertension. 22 A logical extension of this interplay in the NTS among glutamatergic neurotransmission, Fos protein, and AT1R during hypertension is our demonstration that transcriptional regulation of AT1R mRNA reexpression in the dorsomedial medulla by c-fos after baroreceptor activation, which is already present in WKY, is enhanced in SHR.…”
Section: Discussionmentioning
confidence: 99%
“…26 Glutamatergic neurotransmission at the NTS is also involved in the downregulation of AT1R mRNA after baroreceptor activation. 21 Angiotensin and glutamate receptors exhibit augmented interaction in the brain of SHR, 32,33 and an elevated basal Fos expression is present in the NTS during hypertension. 22 A logical extension of this interplay in the NTS among glutamatergic neurotransmission, Fos protein, and AT1R during hypertension is our demonstration that transcriptional regulation of AT1R mRNA reexpression in the dorsomedial medulla by c-fos after baroreceptor activation, which is already present in WKY, is enhanced in SHR.…”
Section: Discussionmentioning
confidence: 99%
“…These nucleotide sequences hybridize with mRNA, thus inhibiting or attenuating the excessive synthesis of vasoconstrictor proteins [12]. Phillips [3, 13] developed two different strategies for hypertension antisense therapy, based on either antisense full-length DNA administered in viral vectors, or antisense oligodeoxynucleotides [14]. The latter are not whole genes, but short lengths of synthetic DNA which may be delivered non-virally (in naked form or in liposomes) intravenously, or even orally, or through skin patches [3].…”
Section: Gene-based Therapy For Hypertension: An Overviewmentioning
confidence: 99%
“…Phillips [3, 13] developed two different strategies for hypertension antisense therapy, based on either antisense full-length DNA administered in viral vectors, or antisense oligodeoxynucleotides [14]. The latter are not whole genes, but short lengths of synthetic DNA which may be delivered non-virally (in naked form or in liposomes) intravenously, or even orally, or through skin patches [3]. With respect to the viral approach, the non-viral procedure is presently safer and, due to its shorter anti-hypertensive effect, more similar to conventional drug therapy.…”
Section: Gene-based Therapy For Hypertension: An Overviewmentioning
confidence: 99%
See 2 more Smart Citations